Cidara Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Cidara Therapeutics (CDTX) with a Buy rating and $41 price target Cidara is developing CD388, the company’s lead influenza drug-Fc conjugate candidate in development for the prevention of all strains of influenza A and B, the analyst tells investors in a research note. The firm says that with a high unmet need, current influenza vaccines and antivirals don’t adequately protect against high risk patient populations.